VH-310 (ex-XV-110)

About Exavir Therapeutics

Exavir Therapeutics is a private, pre-revenue biotech pioneering ultra-long-acting (ULA) antiviral prodrugs, primarily targeting HIV and hepatitis B. Its core technology modifies existing, proven antiretroviral drugs into prodrugs that release the active agent slowly, enabling dosing intervals of up to six months or longer. The company has validated its platform through a significant partnership with ViiV Healthcare (GSK) for its lead asset, VH-310, which is now in Phase 1. Exavir's strategy aims to address major unmet needs in adherence, access, and cost in global antiviral markets.

Therapeutic Areas